Antitumor effects and mechanisms of Ganoderma extracts and spores oil

Chun Chen, Peng Li, Ye Li, Guang Yao, Jian Hua Xu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ganoderma lucidum is a popular herbal medicine used in China to promote health. Modern studies have disclosed that the active ingredients of Ganoderma can exhibit several effects, including antitumor effects and immunomodulation. The present study evaluated the antitumor effects of self-prepared Ganoderma extracts and spores oil, and investigated the possible underlying mechanisms by observing the effects of the extracts and oil on topoisomerases and the cell cycle. The results showed that Ganoderma extracts and spores oil presented dose-dependent inhibitory effects on tumor cells. The half maximal inhibitory concentration (IC50) values of Ganoderma extracts on HL60, K562 and SGC-7901 cells for 24 h were 0.44, 0.39 and 0.90 mg/ml, respectively; for Ganoderma spores oil, the IC50 values were 1.13, 2.27 and 6.29 mg/ml, respectively. In the in vivo study, the inhibitory rates of Ganoderma extracts (4 g/kg/d, intragastrically) on S180 and H22 cells were 39.1 and 44.6%, respectively, and for Ganoderma spores oil (1.2 g/kg/d, intragastrically) the inhibitory rates were 30.9 and 44.9%, respectively. Ganoderma extracts and spores oil inhibited the activities of topoisomerase I and II. Ganoderma spores oil was shown block the cell cycle at the transition between the G1 and S phases and induce a marked decrease in cyclin D1 levels in K562 cells, with no significant change in cyclin E level. These results suggest that the Ganoderma extracts and spores oil possessed antitumor effects in the in vitro and in vivo studies. The antitumor mechanisms of the extracts and spores oil were associated with inhibitory effects on topoisomerase I and II activities, and for Ganoderma spores oil, the antitumor effects may also be associated with decreased cyclin D1 levels, thus inducing G1 arrest in the cell cycle.

Original languageEnglish (US)
Pages (from-to)3571-3578
Number of pages8
JournalOncology Letters
Volume12
Issue number5
DOIs
StatePublished - Nov 1 2016

Fingerprint

Ganoderma
Spores
Oils
Type II DNA Topoisomerase
Type I DNA Topoisomerase
Cyclin D1
Inhibitory Concentration 50
Cell Cycle
Reishi
G1 Phase Cell Cycle Checkpoints
Cyclin E
Immunomodulation
K562 Cells
Herbal Medicine
G1 Phase
S Phase
China

Keywords

  • Cell cycle
  • Cyclin D1
  • Ganoderma extracts
  • Ganoderma spores oil
  • Topoisomerase I and II
  • Tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antitumor effects and mechanisms of Ganoderma extracts and spores oil. / Chen, Chun; Li, Peng; Li, Ye; Yao, Guang; Xu, Jian Hua.

In: Oncology Letters, Vol. 12, No. 5, 01.11.2016, p. 3571-3578.

Research output: Contribution to journalArticle

Chen, Chun ; Li, Peng ; Li, Ye ; Yao, Guang ; Xu, Jian Hua. / Antitumor effects and mechanisms of Ganoderma extracts and spores oil. In: Oncology Letters. 2016 ; Vol. 12, No. 5. pp. 3571-3578.
@article{2b74594239be46ca9372a8f5774839b5,
title = "Antitumor effects and mechanisms of Ganoderma extracts and spores oil",
abstract = "Ganoderma lucidum is a popular herbal medicine used in China to promote health. Modern studies have disclosed that the active ingredients of Ganoderma can exhibit several effects, including antitumor effects and immunomodulation. The present study evaluated the antitumor effects of self-prepared Ganoderma extracts and spores oil, and investigated the possible underlying mechanisms by observing the effects of the extracts and oil on topoisomerases and the cell cycle. The results showed that Ganoderma extracts and spores oil presented dose-dependent inhibitory effects on tumor cells. The half maximal inhibitory concentration (IC50) values of Ganoderma extracts on HL60, K562 and SGC-7901 cells for 24 h were 0.44, 0.39 and 0.90 mg/ml, respectively; for Ganoderma spores oil, the IC50 values were 1.13, 2.27 and 6.29 mg/ml, respectively. In the in vivo study, the inhibitory rates of Ganoderma extracts (4 g/kg/d, intragastrically) on S180 and H22 cells were 39.1 and 44.6{\%}, respectively, and for Ganoderma spores oil (1.2 g/kg/d, intragastrically) the inhibitory rates were 30.9 and 44.9{\%}, respectively. Ganoderma extracts and spores oil inhibited the activities of topoisomerase I and II. Ganoderma spores oil was shown block the cell cycle at the transition between the G1 and S phases and induce a marked decrease in cyclin D1 levels in K562 cells, with no significant change in cyclin E level. These results suggest that the Ganoderma extracts and spores oil possessed antitumor effects in the in vitro and in vivo studies. The antitumor mechanisms of the extracts and spores oil were associated with inhibitory effects on topoisomerase I and II activities, and for Ganoderma spores oil, the antitumor effects may also be associated with decreased cyclin D1 levels, thus inducing G1 arrest in the cell cycle.",
keywords = "Cell cycle, Cyclin D1, Ganoderma extracts, Ganoderma spores oil, Topoisomerase I and II, Tumor",
author = "Chun Chen and Peng Li and Ye Li and Guang Yao and Xu, {Jian Hua}",
year = "2016",
month = "11",
day = "1",
doi = "10.3892/ol.2016.5059",
language = "English (US)",
volume = "12",
pages = "3571--3578",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Antitumor effects and mechanisms of Ganoderma extracts and spores oil

AU - Chen, Chun

AU - Li, Peng

AU - Li, Ye

AU - Yao, Guang

AU - Xu, Jian Hua

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Ganoderma lucidum is a popular herbal medicine used in China to promote health. Modern studies have disclosed that the active ingredients of Ganoderma can exhibit several effects, including antitumor effects and immunomodulation. The present study evaluated the antitumor effects of self-prepared Ganoderma extracts and spores oil, and investigated the possible underlying mechanisms by observing the effects of the extracts and oil on topoisomerases and the cell cycle. The results showed that Ganoderma extracts and spores oil presented dose-dependent inhibitory effects on tumor cells. The half maximal inhibitory concentration (IC50) values of Ganoderma extracts on HL60, K562 and SGC-7901 cells for 24 h were 0.44, 0.39 and 0.90 mg/ml, respectively; for Ganoderma spores oil, the IC50 values were 1.13, 2.27 and 6.29 mg/ml, respectively. In the in vivo study, the inhibitory rates of Ganoderma extracts (4 g/kg/d, intragastrically) on S180 and H22 cells were 39.1 and 44.6%, respectively, and for Ganoderma spores oil (1.2 g/kg/d, intragastrically) the inhibitory rates were 30.9 and 44.9%, respectively. Ganoderma extracts and spores oil inhibited the activities of topoisomerase I and II. Ganoderma spores oil was shown block the cell cycle at the transition between the G1 and S phases and induce a marked decrease in cyclin D1 levels in K562 cells, with no significant change in cyclin E level. These results suggest that the Ganoderma extracts and spores oil possessed antitumor effects in the in vitro and in vivo studies. The antitumor mechanisms of the extracts and spores oil were associated with inhibitory effects on topoisomerase I and II activities, and for Ganoderma spores oil, the antitumor effects may also be associated with decreased cyclin D1 levels, thus inducing G1 arrest in the cell cycle.

AB - Ganoderma lucidum is a popular herbal medicine used in China to promote health. Modern studies have disclosed that the active ingredients of Ganoderma can exhibit several effects, including antitumor effects and immunomodulation. The present study evaluated the antitumor effects of self-prepared Ganoderma extracts and spores oil, and investigated the possible underlying mechanisms by observing the effects of the extracts and oil on topoisomerases and the cell cycle. The results showed that Ganoderma extracts and spores oil presented dose-dependent inhibitory effects on tumor cells. The half maximal inhibitory concentration (IC50) values of Ganoderma extracts on HL60, K562 and SGC-7901 cells for 24 h were 0.44, 0.39 and 0.90 mg/ml, respectively; for Ganoderma spores oil, the IC50 values were 1.13, 2.27 and 6.29 mg/ml, respectively. In the in vivo study, the inhibitory rates of Ganoderma extracts (4 g/kg/d, intragastrically) on S180 and H22 cells were 39.1 and 44.6%, respectively, and for Ganoderma spores oil (1.2 g/kg/d, intragastrically) the inhibitory rates were 30.9 and 44.9%, respectively. Ganoderma extracts and spores oil inhibited the activities of topoisomerase I and II. Ganoderma spores oil was shown block the cell cycle at the transition between the G1 and S phases and induce a marked decrease in cyclin D1 levels in K562 cells, with no significant change in cyclin E level. These results suggest that the Ganoderma extracts and spores oil possessed antitumor effects in the in vitro and in vivo studies. The antitumor mechanisms of the extracts and spores oil were associated with inhibitory effects on topoisomerase I and II activities, and for Ganoderma spores oil, the antitumor effects may also be associated with decreased cyclin D1 levels, thus inducing G1 arrest in the cell cycle.

KW - Cell cycle

KW - Cyclin D1

KW - Ganoderma extracts

KW - Ganoderma spores oil

KW - Topoisomerase I and II

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84990019677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990019677&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.5059

DO - 10.3892/ol.2016.5059

M3 - Article

AN - SCOPUS:84990019677

VL - 12

SP - 3571

EP - 3578

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 5

ER -